Veterinary Neurodegenerative Disease Diagnostics Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The veterinary neurodegenerative disease diagnostics market covers diagnostic technologies used to identify, monitor, and manage progressive neurological conditions in animals, with a focus on companion animals such as dogs and cats. Market value stood at approximately $365 million in 2024, is expected near $434 million in 2026, and is forecast to reach approximately $596 million by 2030 at a compound annual growth rate of about 8.69% from 2025 to 2030. The U.S. segment alone was valued at roughly $105 million in 2024 and is expected to grow to $158 million by 2030.

• •Global market valued at approximately $365 million in 2024; projected to reach ~$596 million by 2030 at ~8.69% CAGR
• •U.S. market generated ~$105 million in 2024 and is forecast to reach ~$158 million by 2030 at ~7.2% CAGR
• •The United States represents approximately 29% of the global market, reflecting a highly concentrated national demand center

Rising research initiatives targeting animal neurological disorders have expanded the pipeline of diagnostic methodologies and increased funding directed at veterinary neuroscience. Growing companion animal ownership, combined with higher spending on pet healthcare, has elevated demand for advanced diagnostic procedures comparable to those available in human medicine. Technological advances in imaging, molecular diagnostics, and biomarker detection are enabling earlier and more accurate identification of neurodegenerative conditions in animals.

• •Increased research funding and institutional initiatives focused on veterinary neurodegenerative disease mechanisms and diagnostics
• •Companion animal population growth and rising per-animal healthcare expenditure driving demand for specialized neurological testing
• •Advances in diagnostic imaging modalities, immunoassay platforms, and molecular biomarkers enabling earlier disease detection

The market is typically segmented by diagnostic modality, including imaging-based diagnostics, biomarker and immunoassay tests, and genetic or molecular diagnostics, as well as by animal type, with companion animals representing the dominant application segment. Geographically, North America, led by the United States, commands the largest share, supported by advanced veterinary healthcare infrastructure and substantial research investment. Europe and the Asia-Pacific region represent secondary growth markets, with increasing companion animal care adoption driving expansion.

• •North America holds the largest regional share, with the U.S. market alone projected to grow from ~$105 million in 2024 to ~$158 million by 2030
• •Companion animals (dogs and cats) constitute the primary application segment, reflecting higher diagnostic intensity and owner investment
• •Europe and Asia-Pacific are emerging growth regions, with rising companion animal healthcare adoption contributing to market expansion

Who are the notable companies in the industry?

The competitive environment reflects a mix of large, diversified animal health organizations alongside smaller specialty diagnostic producers, yielding a moderately fragmented market structure. Integrated animal health companies leverage existing distribution networks and broad product portfolios, while specialty producers focus on niche neurological and molecular diagnostic platforms. IDEXX Laboratories leads the competitive landscape through its wide-ranging diagnostic capabilities, capitalizing on its established position across multiple diagnostic segments, including neurological imaging, laboratory testing, and genetic screening, to serve veterinarians managing neurodegenerative conditions in companion and large animals alike. The competitive landscape is shaped by access to diagnostic technology platforms, regulatory pathways for veterinary diagnostic devices, and the concentration of manufacturing and R&D capacity in North America and Western Europe. As demand for genetic testing and neurological imaging continues to rise, the interplay between comprehensive diagnostic portfolios and specialized molecular platforms will remain a defining dynamic of market competition.

• •Market exhibits moderate fragmentation, with a spectrum ranging from large diversified animal health corporations to smaller specialty diagnostic technology firms
• •Integrated producers leverage broad portfolios and established veterinary distribution channels; specialty producers compete on advanced diagnostic platform differentiation and biomarker innovation
• •Manufacturing and R&D capacity is concentrated in North America and Europe, with regional regulatory and reimbursement frameworks influencing competitive positioning

What are the recent trends and outlook?

The market is expected to sustain an approximate 8.5-8.7% annual growth trajectory through 2030, with longer-term projections extending to nearly $808 million by 2034. Key trends include the translation of human neurodegenerative biomarker research into veterinary applications, the integration of artificial intelligence in diagnostic image interpretation, and growing emphasis on early-intervention screening protocols for aging companion animals. Continued investment in veterinary neuroscience research and expanding access to advanced diagnostic equipment in emerging markets are likely to sustain above-average market growth through the forecast horizon.

• •Market projected to reach ~$596 million by 2030 and ~$808 million by 2034, implying sustained compound annual growth of approximately 8.5% over the longer term
• •Cross-pollination of human neurodegenerative biomarker research into veterinary diagnostics is emerging as a significant innovation driver
• •AI-assisted diagnostic imaging interpretation and early-screening protocols for age-related neurological conditions are gaining adoption in veterinary clinical practice